Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Increasing incidence rate of breast cancer in cystic fibrosis - relationship between pathogenesis, oncogenesis and prediction of the treatment effect in the context of worse clinical outcome and prognosis of cystic fibrosis due to estrogens

N. Stastna, K. Brat, L. Homola, A. Os, D. Brancikova

. 2023 ; 18 (1) : 62. [pub] 20230320

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003772

Cystic fibrosis (CF) is the most common genetic disease in the Caucasion population. Thanks to the CFTR modulators therapy, life expectancy will significantly improve. New therapeutic challenges can be expected, including diseases associated with ageing and higher incidence of cancer, as evidenced by recent epidemiological studies. The increasing incidence of tumors includes also breast cancer. The risk of breast cancer is higher in CF patients compared to the general population. Sex hormones, especially estrogens, also affect on the pathophysiology and immunology of the CF. Previous research, has demonstrated unequivocal survival rates for female CF patients compared to their male counterparts. Is demonstrated, that chemotherapy used for breast cancer affects the CFTR channel and CFTR modulator therapy has frequent side effects on breast tissue. In this review, we focus on the effects of female sex hormones on CF disease, pathophysiological relationships between CF and breast cancer, and the impact of antitumor treatment on both, malignant disease and CF. The potential for further investigation is also discussed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003772
003      
CZ-PrNML
005      
20230425140857.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13023-023-02671-z $2 doi
035    __
$a (PubMed)36941680
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Stastna, Nela $u Department of Respiratory Diseases, University Hospital Brno, Jihlavska 20, Brno, 62500, Czech Republic. stastna.nela@fnbrno.cz $u Faculty of Medicine, Masaryk University Brno, Kamenice 5, Brno, 62500, Czech Republic. stastna.nela@fnbrno.cz $1 https://orcid.org/0000000169069901
245    10
$a Increasing incidence rate of breast cancer in cystic fibrosis - relationship between pathogenesis, oncogenesis and prediction of the treatment effect in the context of worse clinical outcome and prognosis of cystic fibrosis due to estrogens / $c N. Stastna, K. Brat, L. Homola, A. Os, D. Brancikova
520    9_
$a Cystic fibrosis (CF) is the most common genetic disease in the Caucasion population. Thanks to the CFTR modulators therapy, life expectancy will significantly improve. New therapeutic challenges can be expected, including diseases associated with ageing and higher incidence of cancer, as evidenced by recent epidemiological studies. The increasing incidence of tumors includes also breast cancer. The risk of breast cancer is higher in CF patients compared to the general population. Sex hormones, especially estrogens, also affect on the pathophysiology and immunology of the CF. Previous research, has demonstrated unequivocal survival rates for female CF patients compared to their male counterparts. Is demonstrated, that chemotherapy used for breast cancer affects the CFTR channel and CFTR modulator therapy has frequent side effects on breast tissue. In this review, we focus on the effects of female sex hormones on CF disease, pathophysiological relationships between CF and breast cancer, and the impact of antitumor treatment on both, malignant disease and CF. The potential for further investigation is also discussed.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a cystická fibróza $x farmakoterapie $x genetika $7 D003550
650    _2
$a protein CFTR $x genetika $7 D019005
650    _2
$a incidence $7 D015994
650    12
$a nádory prsu $x farmakoterapie $x komplikace $7 D001943
650    _2
$a estrogeny $x terapeutické užití $7 D004967
650    _2
$a prognóza $7 D011379
650    _2
$a karcinogeneze $7 D063646
650    _2
$a pohlavní steroidní hormony $x terapeutické užití $7 D012739
650    _2
$a mutace $7 D009154
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Brat, Kristian $u Department of Respiratory Diseases, University Hospital Brno, Jihlavska 20, Brno, 62500, Czech Republic $u Faculty of Medicine, Masaryk University Brno, Kamenice 5, Brno, 62500, Czech Republic
700    1_
$a Homola, Lukas $u Faculty of Medicine, Masaryk University Brno, Kamenice 5, Brno, 62500, Czech Republic $u Department of Children's Infectious Diseases, University Hospital Brno, Jihlavska 20, Brno, 62500, Czech Republic
700    1_
$a Os, Audun $u Department of Pulmonary Medicine, Oslo University Hospital, Kirkeveien 166, Ullevål, Oslo, 0450, Norway
700    1_
$a Brancikova, Dagmar $u Faculty of Medicine, Masaryk University Brno, Kamenice 5, Brno, 62500, Czech Republic $u Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, Jihlavska 20, Brno, 62500, Czech Republic
773    0_
$w MED00165365 $t Orphanet journal of rare diseases $x 1750-1172 $g Roč. 18, č. 1 (2023), s. 62
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36941680 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140854 $b ABA008
999    __
$a ok $b bmc $g 1924444 $s 1189981
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c 1 $d 62 $e 20230320 $i 1750-1172 $m Orphanet journal of rare diseases $n Orphanet J Rare Dis $x MED00165365
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace